Literature DB >> 1479148

High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991.

C Proye1, M Vix, A Goropoulos, P Kerlo, M Lecomte-Houcke.   

Abstract

In this surgical series of 100 pheochromocytomas (PH), where 91 cases were studied and followed up, the frequency of malignancy appears high (29%) on macroscopic criteria observed at the first operation (25 out 26 cases of malignant PH) or thanks to the occurrence of metastases (1 case out of 26 malignant PH). While some clinical signs are suggestive, there is no excretory profile predictive of malignancy. Isolated or predominant secretion of dopamine is not specific of malignancy event if it occurs more frequently and severely in malignant PH. Bilateral involvement, occurring in the setting of phacomatosis or of multiple endocrine neoplasia (MEN II), or in a sporadic case, is not a predictor for malignancy. Contrarily, extraadrenal involvement is a major feature indicative of malignancy. A CT scan which demonstrates possible locoregional invasion, and a MIGB scan revealing distant localizations raise the suspicion of malignancy. The preferred surgical approach is via a laparotomy, thus allowing the exploration of all possible abdominal chromaffin site and the search for intraabdominal metastases. Intraoperative MIBG scanning checks the completeness of the excision. Flow cytometric DNA ploidy studies have been performed in 25 of our patients. The follow up of benign or malignant PH, after excision "for cure" must be life-long: clinically, biologically and by MIGB scan. Persistence of the disease after surgery or recurrence with unresectable metastases can benefit from MIGB and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1479148     DOI: 10.1007/BF03345810

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  34 in total

1.  Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma.

Authors:  D S Goldstein; R Stull; G Eisenhofer; J C Sisson; A Weder; S D Averbuch; H R Keiser
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391

2.  Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients.

Authors:  C Proye; D Thevenin; P Cecat; P Petillot; B Carnaille; P Verin; M Sautier; N Racadot
Journal:  Surgery       Date:  1989-12       Impact factor: 3.982

3.  Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors:  B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal:  J Nucl Med       Date:  1985-06       Impact factor: 10.057

4.  Limitations of 131I-MIBG scintigraphy in locating pheochromocytomas.

Authors:  I R Gough; N W Thompson; B Shapiro; J C Sisson
Journal:  Surgery       Date:  1985-07       Impact factor: 3.982

5.  A re-evaluation of dopamine excretion in phaeochromocytoma.

Authors:  P A Tippett; A J McEwan; D M Ackery
Journal:  Clin Endocrinol (Oxf)       Date:  1986-10       Impact factor: 3.478

6.  Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion.

Authors:  C Proye; P Fossati; P Fontaine; J Lefebvre; M Decoulx; J L Wemeau; D Dewailly; E Rwamasirabo; P Cecat
Journal:  Surgery       Date:  1986-12       Impact factor: 3.982

7.  Multiple sequential pulmonary resections for metastatic pheochromocytoma with long-term survival.

Authors:  E Abemayor; A H Harken; C E Koop
Journal:  Am J Surg       Date:  1980-11       Impact factor: 2.565

8.  Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s).

Authors:  J A van Heerden; C F Roland; J A Carney; S G Sheps; C S Grant
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

9.  [Dopamine-secreting phaeochromocytoma. A little known clinical and biochemical entity (author's transl)].

Authors:  P Fossati; M Romon-Rousseaux; A Racadot; N Racadot-Leroy; C Proye; J L Wemeau; M Bethouart; M Mazzuca
Journal:  Nouv Presse Med       Date:  1982-05-08

10.  An immunohistochemical study of pheochromocytomas.

Authors:  R V Lloyd; B Shapiro; J C Sisson; V Kalff; N W Thompson; W A Beierwaltes
Journal:  Arch Pathol Lab Med       Date:  1984-07       Impact factor: 5.534

View more
  15 in total

1.  Dna ploidy of pheochromocytoma on cytology specimen by image analysis.

Authors:  Noriko Kimura; Mika Watanabe; Tsuneo Ookuma; Wakako Miura; Takao Noshiro; Yukio Miura; Hiroshi Nagura
Journal:  Endocr Pathol       Date:  1994-09       Impact factor: 3.943

2.  Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.

Authors:  Graeme Eisenhofer; Jacques W M Lenders; Gabriele Siegert; Stefan R Bornstein; Peter Friberg; Dragana Milosevic; Massimo Mannelli; W Marston Linehan; Karen Adams; Henri J Timmers; Karel Pacak
Journal:  Eur J Cancer       Date:  2011-10-28       Impact factor: 9.162

Review 3.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

Review 4.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

5.  Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma.

Authors:  Ian D Tonks; Arne W Mould; Wayne A Schroder; Andrew Cotterill; Nicholas K Hayward; Graeme J Walker; Graham F Kay
Journal:  Neoplasia       Date:  2010-03       Impact factor: 5.715

6.  Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?

Authors:  Amit Agarwal; Prateek K Mehrotra; Manoj Jain; Sushil K Gupta; Anjali Mishra; Gyan Chand; Gaurav Agarwal; A K Verma; S K Mishra; Uttam Singh
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

Review 7.  Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis.

Authors:  Oksana Hamidi; William F Young; Lucinda Gruber; John Smestad; Qi Yan; Oscar J Ponce; Larry Prokop; Mohammad Hassan Murad; Irina Bancos
Journal:  Clin Endocrinol (Oxf)       Date:  2017-08-17       Impact factor: 3.478

8.  A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.

Authors:  A Guha; Z Musil; A Vicha; T Zelinka; K Pacak; J Astl; M Chovanec
Journal:  Neoplasma       Date:  2019-06-29       Impact factor: 2.575

9.  "The" pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist?

Authors:  C A Proye; M Vix; S Jansson; L E Tisell; H Dralle; W Hiller
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

10.  Composite Pheochromocytoma-Ganglioneuroma of the Adrenal Gland: An Uncommon Entity with Distinctive Clinicopathologic Features.

Authors:  King-Yin Lam; Chung-Yau Lo
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.